African-American Women Less Likely to Begin Hormonal Therapy Than White Women
Researchers found that a high number of African-American women don’t start taking hormonal therapy within the first year after a hormone-positive breast cancer diagnosis. These results may partly explain why African-American women have worse breast cancer outcomes than white women.
Background and Goals
For decades, African-American women with breast cancer have been more likely to experience a recurrence, or return, of breast cancer and more likely to die from the disease than white women with breast cancer. This gap is widest in hormone receptor-positive breast cancer, which grows in response to the hormones estrogen or progesterone.
Hormonal therapy, called endocrine therapy in this study, includes tamoxifen, which changes the way the body responds to estrogen, and aromatase inhibitors, which lower the amount of estrogen in the body. These medicines are often prescribed as adjuvant, or post-surgery treatment, to be taken every day for 5 to 10 years. These medicines lower the risk of recurrence by about 40 percent and the risk of death by about 30 percent.
But research has shown that up to a third of all women who are eligible for hormonal therapy never start taking it. It also suggests that by the 5-year mark, half of the women who did start taking it have stopped or are not taking it correctly.
Since not taking hormonal therapy leads to worse outcomes for women with hormone-positive breast cancer and African-American women experience worse outcomes, these researchers wondered if there was a difference in the way African-American and white women take hormonal therapy.
The researchers found records for 2,640 women age 64 and younger who were diagnosed with early-stage, hormone-positive breast cancer between 2004 and 2009. All of the women lived in North Carolina, identified as either white (non-Hispanic) or African-American (non-Hispanic) and had private insurance, such as through an employer.
The study found that African-American women were 17 percent less likely to begin hormonal therapy in the year after their diagnosis than white women were.
Of the 2,640 women in the study,
- 295 (11 percent) were African-American
- 2,345 (89 percent) were white
Within a year of diagnosis, hormonal therapy had been started by
- 79.9 percent of African-American women
- 86.7 percent of white women
Interestingly, researchers found that this gap only existed between women who were treated with chemotherapy. A difference wasn't seen between African-American women and white women when neither group had chemotherapy.
Researchers were unable to know if
- women who did not start hormonal therapy received prescriptions for hormonal therapy that they never filled or if no hormonal therapy was prescribed
- factors such as social support, beliefs, attitudes or interactions with their healthcare team affected how women received treatment
What This Means for You
Perhaps you have heard before that African-American women are less likely to have good outcomes after breast cancer than white women. Perhaps you have even experienced this yourself. But your race should not affect your quality of care.
You may be glad to know that researchers are looking into these issues and that more research on this is planned for the future. These researchers point out that despite the fact that the women in this study were relatively healthy and well-insured, a significant difference was seen between people of different races. That makes them wonder if race also has an effect on how women with access to fewer resources are taking hormonal therapy. They say future studies should look at this question, as these women may experience an even greater gap. They also say future studies will look at whether African-American women who start taking hormonal therapy are taking the recommended dose for the recommended amount of time.
The researchers stress the importance of learning what keeps some African-American women from starting hormonal therapy and creating culturally-sensitive ways to help. They hope this could increase the number of African-American women with hormone-positive breast cancer who are taking hormonal therapy. In turn, this would hopefully help these women live longer, recurrence-free lives.
Reeder-Hayes, Katherine E.; Meyer, Anne Marie; Dusetzina, Stacie B. et al. Racial disparities in initiation of adjuvant endocrine therapy. Breast Cancer Research and Treatment. Volume 145, Issue 3, pages 743–751, June 2014; doi: 10.1007/s10549-014-2957-z.